Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
Holding CORT?
Track your performance easily
CORT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.84 - $43.32
Previous Close$42.27
Volume2.55M
Average Volume (3M)862.03K
Market Cap
$4.42B
Enterprise Value$3.95B
Total Cash (Recent Filing)$473.16M
Total Debt (Recent Filing)$5.67M
Price to Earnings (P/E)37.5
Beta0.55
Next Earnings
Oct 30, 2024EPS Estimate
$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.13
Shares Outstanding104,492,469
10 Day Avg. Volume806,307
30 Day Avg. Volume862,034
Standard Deviation0.14
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)7.40
Price to Sales (P/S)7.28
Price to Cash Flow (P/CF)25.20
P/FCF Ratio25.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.93
Enterprise Value/Gross Profit8.30
Enterprise Value/Ebitda27.09
Forecast
1Y Price Target
$63.33Price Target Upside49.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Corcept Therapeutics News
PremiumCompany Announcements
Corcept Therapeutics Releases Q2 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Market PotentialThe recent prevalence data from the CATALYST study coupled with increasing real-world experience of physicians increasing use in patients with hypercortisolism and uncontrolled T2D adds an additional 1.2M patients to the TAM.
Product ExpansionThe company is expanding into other disease areas, including oncology and metabolic disorders, with an ongoing Phase III trial in platinum-resistant ovarian cancer and earlier phase trials in prostate cancer, amyotrophic lateral sclerosis (ALS), and metabolic dysfunction-associated steatohepatitis (MASH).
Revenue GrowthKorlym sales revenue was $163.8M for the quarter, and beat both our estimate and the Street consensus.
Bears Say
InvestigationsTEVA's accusations of doctor kickbacks is essentially a re-hash of the ongoing NJ USAO's investigations into CORT's sales practices.
Legal IssuesTEVA filed a lawsuit against CORT claiming Korlym's orphan pricing is egregious and that some of CORT's patents are invalid.
Market UncertaintyWith a much greater TAM and pricing in Orphan disease territory, how much begins to be too much for a payer to bear is a very difficult scenario to model for as there are many possible outcomes.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CORT FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest stock price was $20.84 and its highest was $43.32 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Currently, no data Available
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Oct 30, 2024 which is in 41 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Jul 29, 2024. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.09.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is $0.28.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 104,492,470 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of $0.32 in its last earnings report, beating expectations of $0.23. Following the earnings report the stock price went down -1.122%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Among the largest hedge funds holding Corcept Therapeutics Inc.’s share is Royce & Associates LLC. It holds Corcept Therapeutics Inc.’s shares valued at 11M.
---
Corcept Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.33 (49.82% Upside)
$63.33 (49.82% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 23.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $110.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.78%
12-Months-Change
Fundamentals
Return on Equity
24.55%
Trailing 12-Months
Asset Growth
36.20%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
---
CORT Earnings Call
Q2 2024
0:00 / 0:00
---
CORT Stock 12 Month Forecast
Average Price Target
$63.33
▲(49.82% Upside)
Technical Analysis
Best Analysts Covering CORT
1 Year
1 Year Success Rate
13/14 ratings generated profit
1 Year Average Return
+28.97%
reiterated a buy rating last month
Copying Edward Nash's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +28.97% per trade.
---